History of myeloid-derived suppressor cells
Open accessThe DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Abstract
Tumour-induced granulocytic hyperplasia is associated with tumour vasculogenesis and escape from immunity via T cell suppression. Initially, these myeloid cells were identified as granulocytes or monocytes; however, recent studies have revealed that this hyperplasia is associated with populations of multipotent progenitor cells that have been identified as myeloid-derived suppressor cells (MDSCs). The study of MDSCs has provided a wealth of information regarding tumour pathobiology, has extended our understanding of neoplastic progression and has modified our approaches to immune adjuvant therapy. In this Timeline article, we discuss the history of MDSCs, their influence on tumour progression and metastasis, and the crosstalk between tumour cells, MDSCs and the host macroenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immune cells from the myeloid lineage, are a major component of the immunosuppressive TME [93].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“The TME is immunosuppressive, thus rendering the immune system less effective in killing cancer cells.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Goycoolea, A. (1997) · Cited by 3,615
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S.-I., Kitamura, Y., Yoshida, N., Kikutani, H., & Kishimoto, T. (1996) · Nature · doi:10.1038/382635a0 · Cited by 2,338
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y., Silver, M., & Isner, J. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.14.3964 · Cited by 1,856
Research works printed but not linked: 1
- Sonnenfeld A Leukamische reaktiones bei carcinoma Zeitschrift f Klin Med 1929 111
Cited by
Items 901–1,000 of 1,000
Carcinogenesis-relevant biological events in the pathophysiology of the efferocytosis phenomenon
Sarode, G. S., Sarode, S. C., Maniyar, N., Sharma, N. K., & Patil, S. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.343 · Cited by 10
Wang, Y., Sun, N., Luo, Y., Fang, Z., Fang, Y., Tian, J., Yu, Y., Wu, J., & Li, Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6624461 · Cited by 8
Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours
Lutfi, N., Galindo-Campos, M. A., & Yélamos, J. (2021) · Cancers · doi:10.3390/cancers13236008 · Cited by 8
Bioinspired Membrane-Coated Nanoplatform for Targeted Tumor Immunotherapy
Mu, D., He, P., Shi, Y., Jiang, L., & Liu, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.819817 · Cited by 8
TNFSF15 alleviates myeloid-derived suppressor cell-mediated cancer immunosuppression in mice
Zhu, Y.-P., Sun, J., Cao, X., Ding, X., Wang, Y., Han, Q.-J., Wang, J., Li, L., & Zhang, Z. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01663-y · Cited by 8
Zhou, X., Dong-jian, A., Liu, X., Jiang, M., Yuan, C., & Hu, J. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.11.027 · Cited by 7
Rastad, J. L., & Green, W. R. (2018) · ImmunoHorizons · doi:10.4049/immunohorizons.1700066 · Cited by 7
Novel modulation on myeloid-derived suppressor cells (MDSCs) by methionine encephalin (MENK)
Geng, J., Yuan, Y., Jiao, X., Wang, R., Liu, N., Chen, H., Griffin, N., & Shan, F. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.01.012 · Cited by 7
Ahn, A., Park, C., Kim, M., Cho, Y., Jang, S., Bae, M. H., Lee, J., Lee, J., Koh, K., & Im, H. J. (2021) · Annals of Laboratory Medicine · doi:10.3343/alm.2021.41.5.479 · Cited by 7
Nanotechnology: A New Strategy for Lung Cancer Treatment Targeting Pro-Tumor Neutrophils
Zhang, J., Jiang, S., Li, S., Jiang, J., Mei, J., Chen, Y., Ma, Y., Liu, Y., & Liu, Y. (2022) · Engineering · doi:10.1016/j.eng.2022.11.006 · Cited by 7
Zhu, S., Lalani, A., Jin, J., Sant’Angelo, D. B., Covey, L. R., Liu, K., Young, H. A., Ostrand‐Rosenberg, S., & Xie, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167924 · Cited by 7
In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy
Denies, S., Combes, F., Ghekiere, C., Cafferty, S. M., Cicchelero, L., & Sanders, N. N. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.60 · Cited by 7
Wu, Y., Wu, J., Dong, Q., & Guo, N. (2017) · Oncology Letters · doi:10.3892/ol.2017.7513 · Cited by 7
Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells
Margulis, K., Honkala, A. T., Kalashnikova, I. V., Noll, S. E., Hill, M. L., Zare, R. N., & Smith, B. R. (2020) · Nanoscale · doi:10.1039/c9nr06494j · Cited by 7
Bhatt, S., Shen, G.-Q., Li, Y., Qian, S., Ragni, M. V., & Lü, L. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.12.001 · Cited by 7
Induction of arginase-1 in MDSC requires exposure to CD3/CD28 activated T cells
Abdelaal, A. M., Bian, Z., Culpepper, C. D., & Liu, Y. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.198.supp.154.13 · Cited by 7
Oliver, L., Alvarez, R., Diaz, R., Valdés, A., Colligan, S. H., Nemeth, M. J., Twum, D. Y. F., Fernández, A., Fernández-Medina, O., Carlson, L. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004710 · Cited by 6
Maralbashi, S., Aslan, C., Kahroba, H., Javadian, M., Shekari, N., Safarzadeh, E., Salari, F., & Kazemi, T. (2025) · Cancer Investigation · doi:10.1080/07357907.2025.2529878 · Cited by 8
Tanimoto, A., Ramkumar, K., Stewart, C. A., Zhang, B., Concannon, K., Cardnell, R. J., Shen, L., Wang, Q., Wang, J., Gay, C. M., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.12.102 · Cited by 6
Zhao, Q., Wei, T., Ma, R., Fu, Y., Yang, R., Su, Y., Yu, Y., Li, B., & Li, Y. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0109 · Cited by 8
Chen, S., Chen, X., Zhang, P., Chen, S., Wang, X., Luo, Q., Cui, Z., Huang, Y., Wan, L., Hou, X., et al. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.11.28 · Cited by 6
Guo, B., Zheng, Y., Fan, Y., Yang, Y., Wang, Y., Qin, L., An, Y., Xu, X., Zhang, X., Sun, G., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101005 · Cited by 6
Multifaceted role of myeloid-derived suppressor cells in colorectal cancer
Zhang, J., Lian, J., Li, N., Yueying, & Wu, G. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115274 · Cited by 6
Developing immunotherapeutic strategies to target brain tumors
Lieberman, N. A. P., Moyes, K. W., & Crane, C. A. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192470 · Cited by 6
Impact of repeated abdominal surgery on wound healing and myeloid cell dynamics
Esendağlı, G., Yöyen-Ermiş, D., Guseinov, E., Aras, C., Aydin, C., Üner, A., Hamaloğlu, E., & Karakoç, D. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2017.11.030 · Cited by 6
Karlsson, R. T. G., Larsson, P., Рифкатовна, М. Р., Khaja, A. S. S., Sarwar, M., Semenas, J., Chen, S., Hedblom, A., Wang, T., Ekström‐Holka, K., et al. (2020) · Cancers · doi:10.3390/cancers12092719 · Cited by 6
Varela, V. A., Heinen, L. B. D. S., Marti, L. C., Caraciolo, V. B., Datoguia, T. S., Amano, M. T., & Pereira, W. O. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113441 · Cited by 6
Wang, M., Diao, K., Richard, M., Dai, L., Hu, T., & Ding, H. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105548 · Cited by 6
CD157 and CD200 at the crossroads of endothelial remodeling and immune regulation
Katoh, M., & Katoh, M. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.04.01 · Cited by 6
The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy
Puttmann, K. T., Duggan, M. C., Mortazavi, A., Diaz, D. A., Carson, W. E., & Sundi, D. (2019) · Bladder Cancer · doi:10.3233/blc-190219 · Cited by 6
LDGs versus NDGs in patients with oral squamous cell carcinoma (OSCC)
Garley, M., Jabłońska, E., Dziemiańczyk-Pakieła, D., Miltyk, W., Ratajczak–Wrona, W., Borys, J., Moniuszko, M., & Grubczak, K. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155311 · Cited by 6
Isolation and Phenotyping of Splenic Myeloid-Derived Suppressor Cells in Murine Cancer Models
Sanseviero, E., Kim, R., & Gabrilovich, D. I. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-1060-2_3 · Cited by 6
Self-citationAntitumor immunity induced by VE-cadherin modified DC vaccine
Zhou, J., Xi, Y., Mu, X., Zhao, R., Chen, H., Zhang, L., Wu, Y., & Qiu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18654 · Cited by 6
del Pilar, C., Garrido-Matilla, L., del Pozo-Filíu, L., Lebrón‐Galán, R., Arias, R. F., Clemente, D., Alonso, J. R., Weruaga, E., & Díaz, D. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-03000-8 · Cited by 6
Liang, Y., Li, J., Zhang, L., Zhou, J., Liu, M., Peng, X., Zheng, W., & Lai, Z. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15495 · Cited by 5
The role of innate immune cells in modulating vascular dynamics in skin malignancies
Marciniak, M., Stachowicz-Suhs, M., & Wagner, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189331 · Cited by 6
Ma, L., Koehn, B. H., Zaiken, M. C., Hippen, K. L., Smith, K. D., Allred, J. R., Williams, R. L., Yao, K., Fink, J., Saha, A., et al. (2025) · Blood · doi:10.1182/blood.2025028562 · Cited by 6
Unraveling tumor cell‑tumor microenvironment crosstalk through antibody array technologies (Review)
Wang, Y., Luo, S., Hua, D., & Huang, R.-P. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5787 · Cited by 5
Gao, H., Wang, H., Li, X., Zhang, F., Ba, Y., Zhao, J., He, C., Xin, S., Liu, X., & Liang, G. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.08.005 · Cited by 5
Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy
Kapor, S., Radojković, M., & Santibanez, J. F. (2024) · Acta Histochemica · doi:10.1016/j.acthis.2024.152183 · Cited by 5
Xiong, Y., Song, W., Shen, L., Wang, Y., Zhang, J., Hu, M., Liu, Y., Li, J., Musetti, S., Liu, R., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000168 · Cited by 5
The impact of microRNAs on myeloid-derived suppressor cells in cancer
Baghbani, E., Noorolyai, S., Duijf, P. H. G., Silvestris, N., Kolahian, S., Hashemzadeh, S., Baghbanzadeh, A., FallahVazirabad, A., & Baradaran, B. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.04.009 · Cited by 5
Ecological niches for colorectal cancer stem cell survival and thrival
Che, J., & Yu, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135364 · Cited by 5
Insights into N6-methyladenosine (m6A) modification of noncoding RNA in tumor microenvironment
Zhang, Y., Zhan, L., Li, J., Jiang, X., & Li, Y. (2023) · Aging · doi:10.18632/aging.204679 · Cited by 5
Cancer immunotherapy: Targeting immunosuppressive tumor microenvironment
Ahmed, N., Adil, A. M., LAVANYA, V. A., & Jamal, S. (2014) · Oncobiology and Targets · doi:10.4103/2395-4469.145382 · Cited by 6
Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation
Panda, A. K., Bose, S., Sarkar, T., Roy, D., Chakraborty, D., Chakraborty, S., Sarkar, I., & Sa, G. (2017) · The Nucleus · doi:10.1007/s13237-017-0194-7 · Cited by 5
Antitumor effects of targeting myeloid-derived suppressive cells
Zeng, D., Long, H., & Zhu, B. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.52 · Cited by 6
Agrati, C., Biasi, S. D., Fidanza, L., Gibellini, L., Nasi, M., Pinti, M., & Cossarizza, A. (2020) · AIDS · doi:10.1097/qad.0000000000002675 · Cited by 6
Garg, A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-1060-2_11 · Cited by 5
Deißler, A., Penna, A. D., van Geffen, C., González-Menéndez, I., Quintanilla‐Martínez, L., Günther, A., Schneiderhan‐Marra, N., Hartl, D., Nürnberg, B., Königsrainer, A., et al. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.05.003 · Cited by 5
mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD
Li, X., Li, Y., Yu, Q., Xu, L., Fu, S., Wei, C., Wang, L., Luo, Y., Shi, J., Qian, P., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.741911 · Cited by 5
Wen, T., Su, C., Xu, C., Wang, Y., Ma, T., Bai, Z., Zhang, H., & Liu, Z. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02765-9 · Cited by 5
Innate and Adaptive Immune Responses to Cancer
Rausch, M. P., & Hastings, K. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_5 · Cited by 5
Wang, J., Wang, C., Sun, Z., Zhang, A., Niu, Z., Zhang, K., Wang, S., Zhang, C., Shi, X., Dong, Y., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14698-5 · Cited by 4
Balan, D., Kampan, N. C., Shafiee, M. N., Plebanski, M., & Aziz, N. H. A. (2026) · Cancers · doi:10.3390/cancers18020336 · Cited by 4
Song, M., Wang, X., Liang, J., Wang, L., Cai, J., & Zhang, B. (2026) · International Journal of Cancer · doi:10.1002/ijc.70395 · Cited by 4
Péterlin, P., Béné, M. C., Jullien, M., Guillaume, T., Bourgeois, A. L., Garnier, A., Debord, C., Eveillard, M., & Chevallier, P. (2023) · eJHaem · doi:10.1002/jha2.795 · Cited by 4
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac
Fialová, K. O., Ondrák, L., Vlk, M., Kozempel, J., Nováková, K., Nový, Z., Hajduová, K., Hajdúch, M., Petřík, M., Pruszyński, M., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00337-8 · Cited by 5
Dabbèche-Bouricha, E., Araujo, L. M. M., Kato, M., Prévost‐Blondel, A., & Garchon, H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1100793 · Cited by 5
Zhao, C., Liu, L., He, Q., Li, Y., Feng, J., Chen, Y., Li, Y., Xu, X., Zhu, S., Ye, Y., et al. (2024) · Aging · doi:10.18632/aging.205563 · Cited by 4
Dineshkumar, T., Anandan, N., Rajkumar, K., & Indumathi, N. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100440 · Cited by 4
Single‐cell profiling reveals the metastasis‐associated immune signature of hepatocellular carcinoma
Zhong, D., Shi, Y., Ma, W., Liang, Y., Liu, H., Qin, Y., Zhang, L., Yang, Q., Huang, X., Lu, Y., et al. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1264 · Cited by 4
Zhu, Y., Zhou, L., Mo, L., Hong, C., Pan, L., Lin, J., Qi, Y., Tan, S., Qian, M., Hu, T., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300541 · Cited by 4
Myeloid Cells’ Evasion of Melanoma Immunity
Wang, J., & Chen, L. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.251 · Cited by 4
Köhler, N., & Zeiser, R. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_261-1 · Cited by 4
Rase, V. J., Hayward, R., Haughian, J. M., & Pullen, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810299 · Cited by 4
Ben‐Meir, K., Twaik, N., Meirow, Y., & Baniyash, M. (2022) · Current Protocols · doi:10.1002/cpz1.558 · Cited by 4
Guo, X., Yu, S., Ren, X., & Li, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19222 · Cited by 4
A method for separation and purification of mouse splenocytes by density gradient centrifugation
Lu, Y., Fu, C., Xia, C., & Ma, S. (2020) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2020.1821712 · Cited by 4
Editorial: Myeloid-derived suppressor cells: a new therapeutic target in sepsis patients
Stortz, J. A., & Efron, P. A. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ce0317-080r · Cited by 4
White, M. P. J. (2015) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17012330 · Cited by 6
Wang, R., Chen, M., Fu, M., Zhao, W., Zhou, J., Gong, M., Wu, Q., & Wang, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110998 · Cited by 3
Li, Q., Liu, Y., Chen, Y., Huang, Y., Deng, Y., Fan, Q., Huang, L., Liu, X., Ye, J., Li, Y., et al. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00872 · Cited by 3
Кологривова, И. В., Dmitriukov, A. A., Naryzhnaya, N. V., Анатольевна, К. О., Kharitonova, O., Vyrostkova, A. I., Kravchenko, E. S., Stepanov, I. V., Andreev, S. L., Евтушенко, В. В., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15192494 · Cited by 3
Liposomes in tumor treatment: a double-edged sword
Wu, G., Li, H., Liang, Y., Li, S., Li, X., & Saw, P. E. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3059-3 · Cited by 3
Biomarkers for predicting immunotherapy response and resistance in glioblastoma
Kim, S., Abikenari, M. A., Bergsneider, B. H.-L., Kim, L. H., & Lim, M. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1823338 · Cited by 3
Nanomodulation and nanotherapeutics of tumor-microenvironment
Dubey, R., Garg, S. S., & Gupta, J. (2022) · OpenNano · doi:10.1016/j.onano.2022.100099 · Cited by 5
Refaat, Y., Rahman, Y. A., Saleh, M. F. M., Sayed, D. M., & Elzohri, M. H. (2022) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_37_22 · Cited by 3
Guimarães-de-Oliveira, J. C., Diniz-Lima, I., Ferreira-dos-Santos, I. M., da Silva-Júnior, E. B., Covre, L. P., Freire-de-Lima, M., da Fonseca, L. M., Morrot, A., Freire‐de‐Lima, L., Mendonça‐Previato, L., et al. (2025) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202520240985 · Cited by 3
Aintablian, A., Arold, A. M., Alattar, H., Cyran, L., Schoen, C. U., du Plessis, N., Walzl, G., Schaible, U. E., Beilhack, A., Nieuwenhuizen, N. E., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646526 · Cited by 3
Cancer-associated fibroblasts as a potential therapeutic target for thyroid cancers
Chakraborty, K., Rajendran, R. L., Kothiwal, S., Majhi, S., Dey, A., Ghosh, S., Chowdhury, A., Dhara, C., Batabyal, R., Biswas, S., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003352 · Cited by 3
Choi, J., Park, S., Quan, X., Park, J., Kang, M. J., Lee, Y.-J., Lee, S. S., Lim, S.-N., Lee, J., No, T.-H., et al. (2025) · Oncology Research and Treatment · doi:10.1159/000549018 · Cited by 3
The role of CXCL5 in tumor microenvironment: Regulatory mechanisms and therapeutic potential
Yang, X., Kuang, H., Sun, R., Ye, L., Chen, Y., Hu, Z., Deng, C., Li, X., Zhang, L., Wang, Y., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70296 · Cited by 3
Biology of Myeloid-Derived Suppressor Cells
Alicea-Torres, K. M., & Gabrilovich, D. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_10 · Cited by 3
Self-citationMyeloid-derived suppressor cells and their "inconvenient" plasticity
Kochan, G. T. (2018) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2018/2.1135 · Cited by 3
Nadal, C., Béguin, J., Benchekroun, G., & Roux, D. L. (2018) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2018.10.003 · Cited by 3
Заботина, Т. Н., Panchuk, I., Tabakov, D., & Захарова, Е. Н. (2020) · Practical oncology · doi:10.31917/2103249 · Cited by 4
Torreggiani, E., Bononi, I., Pietrobon, S., Mazzoni, E., Guerra, G., Feo, C. V., Martini, F., & Tognon, M. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632129 · Cited by 3
Myeloid-Derived Suppressor Cells in Aged Humans
Rauh, M. J., Cook, E. K., & Bowdish, D. M. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_96 · Cited by 3
Brajer-Luftmann, B., Kaczmarek, M., Nowicka, A., Stelmach-Mardas, M., Wyrzykiewicz, M., Yasar, S. J., Piorunek, T., Sikora, J., & Batura‐Gabryel, H. (2022) · Medicine · doi:10.1097/md.0000000000029208 · Cited by 3
Emerging immune-based technologies for high-grade gliomas
Lucifero, A. G., & Luzzi, S. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2110072 · Cited by 3
Zhu, Z., Shi, L., Dong, Y., Zhang, Y., Yang, F., Wei, J., Huo, M., Li, P., & Liu, X. (2022) · PubMed · Cited by 4
Pu, Z., Zhao, Q., Chen, J., Xie, Y., Mou, L., & Zha, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148130 · Cited by 3
Myeloid‐derived suppressor cells: Are they involved in gestational diabetes mellitus?
Hua, S., Wang, S., Cai, J., Wu, L., & Cao, Y. (2023) · American Journal of Reproductive Immunology · doi:10.1111/aji.13711 · Cited by 3
Heterogeneous characterization of neutrophilic cells in head and neck cancers
Fay, M., Clavijo, P. E., & Allen, C. T. (2024) · Head & Neck · doi:10.1002/hed.27774 · Cited by 3
Role of regulatory immune cells in pathogenesis and therapy of periodontitis
Tan, X., & Li, J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04045-7 · Cited by 3
The Role of Innate Immune Signaling in Regulation of Tumor-Associated Myeloid Cells
Shime, H., Matsumoto, M., & Seya, T. (2015) · Springer eBooks · doi:10.1007/978-4-431-55327-4_3 · Cited by 3
Innate and Adaptive Immune Responses to Cancer
Hastings, K. T., & Rausch, M. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-38983-2_4 · Cited by 3
Dissecting neutrophil complexity in cancer
Ponzetta, A., Mantovani, A., & Jaillon, S. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170062 · Cited by 3
Metadata
- Authors
- Talmadge, J. E., & Gabrilovich, D. I.
- Affiliations
- University of Nebraska Medical Center (US)
- The Wistar Institute (US)
- Corresponding author
- Talmadge, James E.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 739-752
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4358792
- OpenAlex
- W2122403898
- Cited by
- 1,148
- References
- 197
- Citations by year
- 2026: 29 · 2025: 57 · 2024: 80 · 2023: 74 · 2022: 105 · 2021: 132 · 2020: 110 · 2019: 95 · 2018: 101 · 2017: 90 · 2016: 129 · 2015: 93 · 2014: 43 · 2013: 7
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA084488, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor microenvironment, T cell suppression, immune evasion, tumor progression, metastasis, multipotent progenitors
- MeSH terms
- Animals, Antigens, Differentiation, Antigens, Neoplasm, Cell Differentiation, Cell Biology, Hematopoiesis, Extramedullary, Humans, Leukemoid Reaction, Medical Oncology, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Chemokines, Cell Lineage, Tumor Escape, Hematopoietic Stem Cell Mobilization, Myeloid Cells, Myeloid Progenitor Cells, Multipotent Stem Cells, Tumor Burden, History, 20th Century, History, 21st Century, Mice, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.